AR098908A1 - Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida - Google Patents
Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamidaInfo
- Publication number
- AR098908A1 AR098908A1 ARP140104850A ARP140104850A AR098908A1 AR 098908 A1 AR098908 A1 AR 098908A1 AR P140104850 A ARP140104850 A AR P140104850A AR P140104850 A ARP140104850 A AR P140104850A AR 098908 A1 AR098908 A1 AR 098908A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- hidroxifenil
- octahidro
- pirazino
- bencil
- Prior art date
Links
- MHZGAVWIXHVIET-UHFFFAOYSA-N N1(NC=NC=C1)C(=O)N Chemical compound N1(NC=NC=C1)C(=O)N MHZGAVWIXHVIET-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable de este: donde R¹ es un grupo alquilo C₁₋₆; R² y R³ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un grupo alquilo C₁₋₆; X², X³ y X⁴ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un átomo de halógeno; y X⁵ es un átomo de hidrógeno o -P(=O)(OH)₂, tiene una actividad de modulación de vía Wnt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013267687 | 2013-12-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098908A1 true AR098908A1 (es) | 2016-06-22 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104850A AR098908A1 (es) | 2013-12-25 | 2014-12-22 | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9174998B2 (es) |
| EP (1) | EP3088401B1 (es) |
| JP (1) | JP6085040B2 (es) |
| KR (1) | KR102307053B1 (es) |
| CN (1) | CN105873932B (es) |
| AR (1) | AR098908A1 (es) |
| AU (1) | AU2014371148B2 (es) |
| BR (1) | BR112016013572B1 (es) |
| CA (1) | CA2932435C (es) |
| CL (1) | CL2016001419A1 (es) |
| CY (1) | CY1122521T1 (es) |
| DK (1) | DK3088401T3 (es) |
| ES (1) | ES2728353T3 (es) |
| HK (1) | HK1222656A1 (es) |
| HR (1) | HRP20190908T1 (es) |
| HU (1) | HUE044541T2 (es) |
| IL (1) | IL245961A0 (es) |
| JO (1) | JO3809B1 (es) |
| LT (1) | LT3088401T (es) |
| ME (1) | ME03391B (es) |
| MX (1) | MX365376B (es) |
| MY (1) | MY173946A (es) |
| PE (1) | PE20160932A1 (es) |
| PH (1) | PH12016501079A1 (es) |
| PL (1) | PL3088401T3 (es) |
| PT (1) | PT3088401T (es) |
| RS (1) | RS58955B1 (es) |
| RU (1) | RU2669805C2 (es) |
| SG (1) | SG11201604496YA (es) |
| SI (1) | SI3088401T1 (es) |
| TR (1) | TR201908392T4 (es) |
| TW (1) | TWI681961B (es) |
| UA (1) | UA116923C2 (es) |
| WO (1) | WO2015098853A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) * | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| RU2723551C2 (ru) * | 2015-06-23 | 2020-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| BR112019014127A2 (pt) * | 2017-02-08 | 2020-02-11 | Eisai R&D Management Co., Ltd. | Composição farmacêutica para tratamento de tumores |
| AU2020374883A1 (en) | 2019-10-29 | 2022-05-26 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist, a VEGFR/FGFR/RET tyrosine kinase inhibitor and a CBP/beta-catenin inhibitor for treating cancer |
| US11655253B2 (en) | 2020-03-12 | 2023-05-23 | 3+2 Pharma, Llc | CBP/catenin signaling pathway inhibitors and uses thereof |
| JPWO2022092294A1 (es) | 2020-10-30 | 2022-05-05 | ||
| WO2023027888A1 (en) * | 2021-08-26 | 2023-03-02 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| WO2023038030A1 (ja) | 2021-09-08 | 2023-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 固形腫瘍治療用医薬組成物 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| WO2023190748A1 (ja) * | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| CN100475816C (zh) * | 2001-10-12 | 2009-04-08 | 中外药品株式会社 | 回折模拟物及其相关的方法 |
| US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| HUE025831T2 (en) | 2008-06-06 | 2016-04-28 | Prism Pharma Co Ltd | Alpha-helix mimetics and related procedures |
| US20100267672A1 (en) * | 2009-04-15 | 2010-10-21 | Choongwae Pharma Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2012050393A2 (ko) * | 2010-10-14 | 2012-04-19 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| WO2012115286A1 (en) * | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja active Application Filing
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active IP Right Grant
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
- 2016-09-13 HK HK16110848.5A patent/HK1222656A1/zh unknown
-
2019
- 2019-05-16 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098908A1 (es) | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida | |
| PE20151606A1 (es) | DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| EA201591457A8 (ru) | Терапевтические соединения | |
| AR089623A1 (es) | Inhibidores de iap | |
| PH12014502739A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ724503A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| AR093767A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos | |
| MX2015012629A (es) | Compuestos de imidazo piridina. | |
| RS54730B1 (sr) | Inhibitori beta sekretaze | |
| CR20130539A (es) | Triazolopiridinas | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| JP2015518492A5 (es) | ||
| JP2014521346A5 (es) | ||
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos | |
| CY1118079T1 (el) | Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
| AR101222A1 (es) | Derivados de piridona | |
| AR098215A1 (es) | Compuesto heterocíclico | |
| ECSP13012365A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| EA201690908A1 (ru) | Пиразолопиримидиновые соединения | |
| NZ715554A (en) | Method of treating hypertrophic cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |